MoonLake Immunotherapeutics(MLTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MLTX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for MoonLake Immunotherapeutics (MLTX), a Healthcare sector company. MLTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), MoonLake Immunotherapeutics reports net income of $-61.8M, free cash flow of $-55.6M. Top institutional holders of MLTX by reported 13-F value include BVF, Deep Track Capital, T. Rowe Price Investment Management, based on the most recent SEC filings. MLTX trades on the Nasdaq exchange and files with the SEC under CIK 1821586. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MLTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MoonLake Immunotherapeutics directly from SEC EDGAR.
Net Income
Q2 2026
$-61.8M
Free Cash Flow
Q2 2026
$-55.6M
ROIC
Q2 2026
-46.7%
D/E Ratio
Q2 2026
0.23
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-91.1% YoYOperating Income
-71.1% YoYEPS (Diluted)
-86.8% YoYTotal Assets
-11.2% YoYTotal Debt
Op. Cash Flow
-68.1% YoYFree Cash Flow
-67.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-227.3M -91.1% | $-118.9M -230.3% | $-36.0M +27.9% | $-50.0M -1000.1% | $-4.5M | — |
| Operating Income | $-244.8M -71.1% | $-143.1M -164.4% | $-54.1M +16.8% | $-65.1M -1323.6% | $-4.6M | — |
| EPS (Diluted) | $-3.53 -86.8% | $-1.89 -158.9% | $-0.73 +57.1% | $-1.70 | — | — |
| Total Assets | $424.4M -11.2% | $477.9M -9.2% | $526.5M +585.2% | $76.8M +693.6% | $9.7M -91.7% | $116.6M |
| Total Debt | $74.1M | $0.00 | — | $0.00 -100.0% | $15.0M | — |
| Operating Cash Flow | $-196.0M -68.1% | $-116.6M -172.5% | $-42.8M +23.5% | $-55.9M -9046.9% | $-611.1K | — |
| Free Cash Flow | $-196.0M -67.4% | $-117.1M -171.9% | $-43.1M +23.0% | $-55.9M | — | — |
Get alerted when MLTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MoonLake Immunotherapeutics including:
Top Institutional Holders of MLTX
BVF INC/IL
$311.5M16,001,284 shDeep Track Capital, LP
$136.3M6,999,025 shT. Rowe Price Investment Management, Inc.
$83.3M4,280,624 shD. E. Shaw & Co., Inc.
$65.5M3,365,507 shCormorant Asset Management, LP
$62.4M3,205,433 shJupiter Topco LLC
$60.1M3,085,906 shLogos Global Management LP
$52.1M2,675,000 shWeiss Asset Management LP
$50.3M2,581,813 shCITADEL ADVISORS LLC
$38.4M1,972,893 shTWO SIGMA INVESTMENTS, LP
$33.4M1,715,349 sh
| Fund | Value | Shares |
|---|---|---|
| BVF INC/IL | $311.5M | 16,001,284 |
| Deep Track Capital, LP | $136.3M | 6,999,025 |
| T. Rowe Price Investment Management, Inc. | $83.3M | 4,280,624 |
| D. E. Shaw & Co., Inc. | $65.5M | 3,365,507 |
| Cormorant Asset Management, LP | $62.4M | 3,205,433 |
| Jupiter Topco LLC | $60.1M | 3,085,906 |
| Logos Global Management LP | $52.1M | 2,675,000 |
| Weiss Asset Management LP | $50.3M | 2,581,813 |
| CITADEL ADVISORS LLC | $38.4M | 1,972,893 |
| TWO SIGMA INVESTMENTS, LP | $33.4M | 1,715,349 |
More Healthcare Companies
View all Healthcare →Put MLTX on your watchlist
Track score changes the day MoonLake Immunotherapeutics files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MLTX a good stock to buy?
13F Pro's AI-powered analysis of MoonLake Immunotherapeutics (MLTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MLTX are available on the MLTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MLTX is classified as a small company.
Which hedge funds own MLTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MLTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MoonLake Immunotherapeutics's investment landscape.